Soleus Capital Management’s Crescent Biopharma CBIO Stock Holding History

Soleus Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$2.38M	–	103
2025 Q3	$2.38M	Sell	200,000 -200,000	-50%	-$2.65M	0.12%	70
2025 Q2	$6.46M	Buy	+400,000	New	+$8.46M	0.43%	50

Other funds holding CBIO

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Soleus Capital Management's CBIO Position: Q4 2025 in Review

Soleus Capital Management sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 200,000 shares — an estimated $2.38M sold.

Soleus Capital Management first reported a position in CBIO in Q2 2025 and held it in 2 quarters. The position peaked at $6.46M in Q2 2025. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

Soleus Capital Management reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
Soleus Capital Management sold 200,000 Crescent Biopharma shares in Q4 2025, an estimated $2.38M.
Soleus Capital Management first reported a position in Crescent Biopharma in Q2 2025 and held it in 2 quarters.
Soleus Capital Management's Crescent Biopharma position peaked at $6.46M in Q2 2025.
58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Soleus Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.